Exicted people cheering in an audience at a game

Living with PI

Treating PI

Immunoglobulin (IG) therapy

Having PI isn’t easy,
BUT treatment can truly help

2 TYPES OF IG THERAPY

Which

Immunoglobulin (Ig) therapy is the standard of care for people with antibody deficiencies like most primary immunodeficiencies (PIs). Ig is given intravenously or subcutaneously and replaces the antibodies that you may be missing. The result is that you will be better protected against infections.


is right for you?

Intravenous Ig (IVIg) Infusion

  • Infused into a vein by a healthcare professional
  • Requires traveling to an infusion center or scheduling visits with a healthcare professional (every 3 to 4 weeks)
  • Can mean spending 4 to 8 hours, or longer, getting your infusion

With Hizentra®

Subcutaneous Ig (SCIg) Infusion

  • Self-infused under the skin—never into a vein
  • Continuous Ig levels for consistent protection against infections
  • After consulting with your doctor, control over where and when you self-infuse
IVIg vs SCIg

Need help deciding?

Watch this video explaining the differences between IVIg and SCIg.

Woman researching on laptop
WHY SCIg?

Self-infusing lg
might be
right for you

In a CSL-sponsored Harris Poll survey of people with PI who have used both IVIg and SCIg,* 4 out of 5 preferred self-infused lg over IVIg.

four out of five people illustration

*In an online survey, 41 of 52 adults with PI who have used both IVIg and SCIg preferred SCIg.

Janet, a Hizentra patient advocate

“Now that I've been self-infusing with HIZENTRA for almost 12 years, my confidence has really grown. If you're going to be doing this every week or two for the rest of your life, you want to feel good about it.

Janet

Patient advocate on Hizentra

Sign up for emails icon

Let's keep the
conversation going

Get the latest resources on PI and updates from Hizentra.

Connect with us

Patient advocates are not healthcare providers or medical experts. For medical questions, please contact your physician. Patient advocates are compensated by CSL Behring LLC for their time and/or expenses.

Learn why Hizentra may be a strong choice for you

Important Safety Information

WARNING: Thrombosis (blood clots) can occur with immune globulin products, including Hizentra. Risk factors can include: advanced age, prolonged immobilization, a history of blood clotting or hyperviscosity (blood thickness), use of estrogens, installed vascular catheters, and cardiovascular risk factors.

If you are at high risk of blood clots, your doctor will prescribe Hizentra at the minimum dose and infusion rate practicable and will monitor for signs of clotting events and hyperviscosity. Always drink sufficient fluids before infusing Hizentra.

See your doctor for a full explanation, and the full prescribing information for complete boxed warning.

Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid, is a prescription medicine used to treat:

  • Primary immune deficiency (PI) in patients 2 years and older
  • Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults

Treatment with Hizentra might not be possible if your doctor determines you have hyperprolinemia (too much proline in the blood), or are IgA-deficient with antibodies to IgA and a history of hypersensitivity. Tell your doctor if you have previously had a severe allergic reaction (including anaphylaxis) to the administration of human immune globulin. Tell your doctor right away or go to the emergency room if you have hives, trouble breathing, wheezing, dizziness, or fainting. These could be signs of a bad allergic reaction.

Inform your doctor of any medications you are taking, as well as any medical conditions you may have had, especially if you have a history of diseases related to the heart or blood vessels, or have been immobile for some time. Inform your physician if you are pregnant or nursing, or plan to become pregnant.

Infuse Hizentra under your skin only; do not inject into a blood vessel.

Self-administer Hizentra only after having been taught to do so by your doctor or other healthcare professional, and having received dosing instructions for treating your condition.

Immediately report to your physician any of the following symptoms, which could be signs of serious adverse reactions to Hizentra:

  • Reduced urination, sudden weight gain, or swelling in your legs (possible signs of a kidney problem).
  • Pain and/or swelling or discoloration of an arm or leg, unexplained shortness of breath, chest pain or discomfort that worsens on deep breathing, unexplained rapid pulse, or numbness/weakness on one side of the body (possible signs of a blood clot).
  • Bad headache with nausea; vomiting; stiff neck; fever; and sensitivity to light (possible signs of meningitis).
  • Brown or red urine; rapid heart rate; yellowing of the skin or eyes; chest pains or breathing trouble; fever over 100°F (possible symptoms of other conditions that require prompt treatment).

Hizentra is made from human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.

The most common side effects in the clinical trials for Hizentra include redness, swelling, itching, and/or bruising at the infusion site; headache; chest, joint or back pain; diarrhea; tiredness; cough; rash; itching; fever, nausea, and vomiting. These are not the only side effects possible. Tell your doctor about any side effect that bothers you or does not go away.

Before receiving any vaccine, tell immunizing physician if you have had recent therapy with Hizentra, as effectiveness of the vaccine could be compromised.

Please see full prescribing information for Hizentra, including boxed warning and the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You can also report side effects to CSL Behring's Pharmacovigilance Department at 1-866-915-6958.

View information about Hizentra for:
You are leaving the current website.

The site you are accessing is maintained by a third party over whom CSL Behring has no control. CSL Behring does not review, approve, or necessarily endorse viewpoints, inferences, or conclusions stated in or implied by the content of this site. CSL Behring is not responsible for third-party content or the consequences of your use thereof.

Do you want to continue?